Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Fig. 1

Pharmacokinetics. a Cmax (left Y-axis) and AUC (right Y-axis) are plotted as a function of dose (X-axis). Dose-linear pharmacokinetics were observed. n = 3–6. b Dose-dependent pharmacokinetic profiles are shown. Cmax was reached at the end of infusion and balixafortide was cleared quickly from the circulation thereafter. n = 3–6. c Comparative pharmacokinetics of balixafortide (1000 µg/kg) infused over 1 vs. 2 h. Cmax was higher and reached earlier for 1-h dosing, but AUC was similar (data not shown). n = 3. d Comparative pharmacokinetics of linear vs. ramped infusion rate at the 2000 µg/kg dose level. Cmax was notably higher but AUC was virtually identical for both infusion types. n = 3. Mean ± SEM are shown throughout

Back to article page